CIK: 0001388325 · Show all filings
Period: Q3 2017 (← Previous) (Next →)
Filing Date: Nov 14, 2017
Total Value ($000): $768,329 (99.1% shares, 0.9% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| INGN | INOGEN INC | 3,549,320 | $337,540 | 43.9% | $17.78 | +442.2% | COM | 45780L104 |
| — | ACCELERON PHARMA INC | 1,553,937 | $57,993 | 7.5% | $27.65 | — | COM | 00434H108 |
| — | DERMIRA INC | 1,921,580 | $51,883 | 6.8% | $30.22 | — | COM | 24983L104 |
| CRVS | CORVUS PHARMACEUTICALS INC | 3,244,046 | $51,710 | 6.7% | $14.33 | -3.5% | COM | 221015100 |
| ANAB | ANAPTYSBIO INC | 1,190,604 | $41,612 | 5.4% | $23.32 | +15.7% | COM | 032724106 |
| AKBA | AKEBIA THERAPEUTICS INC | 1,887,535 | $37,128 | 4.8% | $10.82 | +42.1% | COM | 00972D105 |
| — | FLEXION THERAPEUTICS INC | 1,500,000 | $36,270 | 4.7% | $16.59 | — | COM | 33938J106 |
| — | RA PHARMACEUTICALS INC | 2,031,562 | $29,661 | 3.9% | $15.19 | — | COM | 74933V108 |
| — | MERUS N V | 1,410,417 | $28,025 | 3.6% | $7.99 | — | COM | N5749R100 |
| — | NABRIVA THERAPEUTICS PLC | 2,903,800 | $23,782 | 3.1% | $10.02 | — | SHS | G63637105 |
| — | REATA PHARMACEUTICALS INC | 592,794 | $18,436 | 2.4% | $19.75 | — | CL A | 75615P103 |
| KALV | KALVISTA PHARMACEUTICALS INC | 2,725,283 | $18,341 | 2.4% | $7.37 | -3.3% | COM | 483497103 |
| — | INVUITY INC | 1,363,848 | $12,138 | 1.6% | $9.51 | — | COM NEW | 46187J205 |
| — | VERONA PHARMA PLC | 740,740 | $11,370 | 1.5% | $11.66 | — | SPONSORED ADS | 925050106 |
| — | WRIGHT MED GROUP N V | 4,622,032 | $7,164 | 0.9% | $1.25 | — | RIGHT 03/01/2019 | N96617126 |
| CRSP | CRISPR THERAPEUTICS AG | 223,317 | $3,991 | 0.5% | $18.69 | -3.0% | NAMEN AKT | H17182108 |
| — | APOLLO ENDOSURGERY INC | 274,472 | $1,285 | 0.2% | $12.16 | — | COM | 03767D108 |